Home / Compare / Henry vs MEDVi
Henry Meds vs MEDVi (2026): the cheapest independently reported duo, and the asterisk each one carries
These are the two lowest independently reported tirzepatide programs we track, and each hides its catch in a different place. Henry Meds' ~$179/month headline covers its tablet and sublingual formats — which have no published human absorption data for tirzepatide — while third-party checks put Henry's injectable near $399–449. MEDVi's ~$199 is a genuine injectable entry price, but its maintenance-dose cost is unconfirmed, and dose-based repricing is where budgets die. For an injectable buyer comparing the two as marketed: MEDVi's $199 is the more honest starting number; Henry's $179 is a different product category wearing a lower price. Both lose to the operator-supplied $139–169 floor if that floor verifies — the ladder's central open question.
Henry: the format is the fine print
Henry's value proposition reads simply — flat ~$179, no membership gymnastics, an established brand — until you notice which formats carry the price. The tablet and sublingual tirzepatide bundle is the $179 product, and everything our namesake analysis establishes applies to it: a 4,814-dalton peptide, no SNAC-class carrier, no published pharmacokinetics, and a one-email test (ask for plasma-concentration data) that, as of this writing, no compounded tablet seller has passed. Henry's injectable exists at roughly brand-vial prices — $399–449 reported — which quietly concedes the point: the company prices the evidenced format like the evidenced format. If you want Henry specifically, the injectable is the product to discuss; if you want the $179, be clear-eyed that you're buying the format bet, and run the email first.
MEDVi: the maintenance question is the fine print
MEDVi's ~$199 is the cleanest independently reported injectable entry in the ledger — which makes the unanswered question louder: what does month six cost at 7.5–10 mg? Dose-based repricing is legal, common, and invisible in headline prices; a $199-at-2.5 mg program that runs $300+ at maintenance is a $300+ program with a promotional quarter, and no third-party source we accept has pinned MEDVi's curve. The defensive purchase is the same one this site keeps prescribing: the maintenance price in writing before payment, the pharmacy name through the license lookup, the cancellation terms as text. MEDVi's fact sheet tracks exactly these open items, and a single reader receipt showing a maintenance-dose invoice would upgrade this whole comparison.
The decision for an injectable buyer
Head-to-head as marketed: MEDVi for anyone who wants the evidenced format at the lowest reported entry, with the maintenance question asked at intake; Henry's injectable only if its ~$399–449 reported band beats your brand-vial math, which — after Lilly's cut to $299–449 — it generally doesn't; Henry's $179 bundle only for someone who has read the tablet evidence and is knowingly buying the bet. And over both hangs the ladder's real question: the operator-supplied $139–169 floor at NexLife (our partner, labeled as always) and the reported $139 at BMI Doctors, either of which — verified — would make this entire duo the second tier. The finder weighs all of it by your answers.
Related: NexLife vs Henry · the $139 twins · the full ladder
The one question each program must answer, and the tiebreaker
Strip the branding and each side of this budget-tier matchup carries exactly one unresolved question. Henry's is which price: our dataset holds a three-way conflict on its injectable ($269 in the April comparison versus $399–449 in earlier reporting) alongside a $179 tablet line whose absorption evidence is the one email nobody has answered — so a Henry decision starts with a checkout screenshot and, for the oral products, the PK question. MEDVi's is which month: the $199 entry figure is the budget tier's best-corroborated number, and its silence on maintenance-dose pricing is where dose-based programs traditionally hide the real cost — so a MEDVi decision starts with the months-four-through-twelve question in writing. The tiebreaker when both answer cleanly: Henry's seniority and review volume favor buyers who value an established operator; MEDVi's entry price favors pure budget shoppers who confirmed it survives titration. And the exit both should check first: at these prices' upper answers, the ledger's verified floor ($119–129 reported) and the brand vials ($299+) bracket the decision from below and above.
Head-to-head FAQ
Is Henry Meds or MEDVi cheaper?
At entry, MEDVi's corroborated $199 undercuts Henry's disputed injectable figures ($269–449 across sources). Henry's cheaper line is its $179 tablets — a format with no published human absorption data, which changes the question entirely.
Is MEDVi's $199 price real?
It's the budget tier's most independently repeated entry figure, confirmed at the source we fetched. What's unconfirmed is the price at maintenance doses — get that in writing before subscribing.
Should I buy Henry's tirzepatide tablets instead of injections?
Not before the absorption question is answered — no compounded oral tirzepatide has published human pharmacokinetics, and Henry prices its evidenced injectable at roughly double its unevidenced tablets. Ask for plasma data first; that email has never been answered by anyone.